Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

被引：0

作者：

Kelly, Karen

Mazieres, Julien

Leighl, Natasha B.

Barlesi, Fabrice

Zalcman, Gerard

Gordon, Michael S.

Reckamp, Karen L.

Gandara, David R.

Gomez-Roca, Carlos Alberto

Bennouna, Jaafar

Cho, Byoung Chul

Park, Keunchil

Infante, Jeffrey R.

Richards, Donald A.

Wu, Yuehui

Schramek, Daniel J.

Cox, Donna S.

Gardner, Olivia S.

Peddareddigari, Vijay Gopal Reddy

Blumenschein, George R.

机构：

[1] UC Davis Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA

[2] Hop Larrey CHU Toulouse, Toulouse, France

[3] Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Aix Marseille Univ, Hop Nord, Assistance Publ Hop Marseille, Marseille, France

[5] Caen Univ Hosp, Caen, France

[6] Pinnacle Oncol Hematol, Scottsdale, AZ USA

[7] City Hope Comprehens Canc Ctr, Duarte, CA USA

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

[9] Inst Claudius Regaud, Toulouse, France

[10] Inst Cancerol Ouest, Nantes, France

[11] Yonsei Univ, Coll Med, Seoul, South Korea

[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[13] Sarah Cannon Res Inst, Nashville, TN USA

[14] Tennessee Oncol, Nashville, TN USA

[15] Texas Oncol, Houston, TX USA

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8027

引用

页数：1

共 50 条

[31] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Sequist, L.
Gray, J.
Harb, W.
Doebele, R.
Modiano, M.
Jackman, D.
Baggstrom, M.
Atmaca, A.
Felip, E.
Provencio, M.
Cobo Dols, M.
Adiwijaya, B.
Kuesters, G.
Kamoun, W.
Andreas, K.
Pipas, J.
Santillana, S.
Cho, B. C.
Park, K.
Shepherd, F.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
[32] CIRCULATING CYTOKINES AND ANGIOGENIC FACTORS (CAFS) AS MARKERS OF CLINICAL RESPONSE IN A RANDOMIZED PHASE II STUDY OF TRAMETINIB VS DOCETAXEL FOR PATIENTS WITH KRAS-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) (MEK114653, NCT01362296)
Tran, Hai T.
Liu, Yuan
Gagnon, Robert C.
Rappold, Erica
Blumenschein, George R.
Peddareddigari, Vijay G. R.
Wu, Frank S.
Heymach, John
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S801 - S802
[33] ERCC1 MRNA EXPRESSION AND KRAS MUTATION STATUS IN EGFR WILD TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Metro, Giulio
Cenci, Matteo
Siggillino, Annamaria
Chiari, Rita
Tofanetti, Francesca R.
Giannarelli, Diana
Pistola, Lorenza
Flacco, Antonella
Bennati, Chiara
Bellezza, Guido
Baglivo, Sara
Sidoni, Angelo
Ludovini, Vienna
Crino, Lucio
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S794 - S794
[34] Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib: a case report
Jiang, Ya
Liu, Xin
Lv, Dong-Lai
Zhao, Xi-Long
ANTI-CANCER DRUGS, 2022, 33 (01) : E752 - E755
[35] Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell Lung Cancer
Lee, Sang Hoon
Kim, Eun Young
Han, Jung Min
Han, Gyoonhee
Chang, Yoon Soo
CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 851 - 864
[36] A phase 1/2 trial of selinexor combined with docetaxel for previously treated, advanced KRAS mutant non-small cell lung cancer
Gupta, A.
West, H.
Camidge, D. R.
Stinchcombe, T. E.
Horn, L.
Saltarski, J.
Bolluyt, J.
White, M. A.
Gerber, D. E.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S118 - S118
[37] A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
Bedard, Philippe
Tabernero, Josep
Kurzrock, Razelle
Britten, Carolyn D.
Stathis, Anastasios
Manuel Perez-Garcia, Jose
Zubel, Angela
Le, Ngocdiep T.
Carter, Kirsten
Bellew, Kevin M.
Gallarati, Chiara
Niazi, Faiz
Demanse, David
De Buck, Stefan S.
Sessa, Cristiana
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38] A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non-small cell lung cancer (NSCLC).
Camidge, D. Ross
Reuss, Joshua E.
Spira, Alexander I.
Janne, Pasi A.
Rehman, Muneeb
Pachter, Jonathan A.
Patrick, Gloria
Denis, Louis J.
Spigel, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Phase I/II trial of combination nab-paclitaxel and pemetrexed in advanced solid tumor patients (pts) with emphasis on non-small cell lung cancer (NSCLC).
Riess, Jonathan
Ho, Cheryl
Davies, Angela M.
Lau, Derick
Lara, Primo
Chew, Helen K.
Beckett, Laurel
Sangha, Randeep S.
Mack, Philip C.
Gandara, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[40] A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models
Beltran, Pedro J.
Zhan, Jinghui
Mitchell, Petia
Wurz, Ryan P.
Pettus, Liping
Wu, Tian
Chaves, Mary
Reid, Darren L.
Radinsky, Robert
Cooke, Keegan
Tasker, Andrew
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →